Z-drugs — zolpidem (Ambien), eszopiclone (Lunesta), zaleplon (Sonata) — are GABA-A positive allosteric modulators with relative selectivity for the α1 subunit. The selectivity is what was supposed to differentiate them from benzodiazepines: predominantly sedative effect with less anxiolytic, muscle relaxant, and anticonvulsant activity. In practice, the mechanism family is the same and most BZD concerns apply.
- Class
- Non-benzodiazepine hypnotics (z-drugs)
- Mechanism
- GABA-A positive allosteric modulators with relative selectivity for α1 subunit (sedative effect predominant; less anxiolytic, muscle relaxant, anticonvulsant)
- Typical dose
- Zolpidem 5-10 mg HS (5 mg women per FDA — slower clearance); eszopiclone 1-3 mg HS; zaleplon 5-20 mg HS
- Half-life
- Zolpidem ~2.5h; eszopiclone ~6h; zaleplon ~1h
- FDA indications
- Insomnia
- Key adverse effects
- Complex sleep behaviors (sleep-driving, sleep-eating — black box), morning sedation/cognitive impairment (especially zolpidem in women, elderly), falls, anterograde amnesia, tolerance, dependence, withdrawal
- Representative agents
- Zolpidem (Ambien), eszopiclone (Lunesta), zaleplon (Sonata)
Black box: Complex sleep behaviors including sleep-driving, sleep-eating, sleep-walking — sometimes resulting in serious injuries or death. Discontinue immediately if these occur.
Marketed as "safer" alternatives to benzodiazepines, but same GABA-A mechanism, similar dependence potential, plus unique complex sleep behavior risk. Short-term use recommended. FDA lowered zolpidem doses in women (slower clearance). CBT-I is preferred long-term for chronic insomnia.
The marketing positioned z-drugs as "safer than benzodiazepines" for sleep. The marketing was incomplete. Z-drugs produce tolerance, dependence, and withdrawal similar to BZDs. They affect cognition and motor coordination. They contribute to falls in elderly patients. They produce next-morning impairment that affects driving.
The Z-drugs are non-benzodiazepine hypnotics that act at the same GABA-A receptor but with selectivity intended to favor sleep over the broader benzodiazepine effects.
Mechanism note: Z-drugs are GABA-A hypnotics with a sleep-selective tilt, but they share the benzodiazepine liabilities — tolerance, dependence, falls, cognitive cost — and are not a safe long-term solution.
They also have a distinct adverse effect family: complex sleep behaviors. Sleep-driving, sleep-eating, sleep-walking, sleep-cooking, sleep-sex — all performed while clinically asleep, with no memory the next day. Some have resulted in motor vehicle accidents, injuries, and deaths. The FDA added a black-box warning. Risk is highest with zolpidem. Any complex behavior should prompt immediate discontinuation.
The FDA also lowered the recommended zolpidem dose in women — 5 mg vs the prior 10 mg standard — because of slower clearance in women producing higher next-morning levels and driving impairment data. Counseling about driving the following day matters.
For acute, short-term insomnia, z-drugs work and are reasonable. For chronic insomnia, CBT-I — cognitive behavioral therapy for insomnia — is the evidence-based first-line treatment, with more durable effect than any pharmacologic intervention. Z-drugs as long-term treatment for chronic insomnia carry meaningful risks without meaningful durability.
- Cost
- Zolpidem generic ~$5-20/month. Eszopiclone generic ~$15-40/month. Zaleplon generic ~$30-60/month.
- Generic status
- All generic.
- Formulary typical
- Generics Tier 1-2.
- Access friction
- Schedule IV. Many plans require step therapy (try cheaper alternatives first) for the more expensive z-drugs.
Prescriber tip: Zolpidem is the default when z-drug is chosen. Counsel about complex sleep behaviors and morning impairment. Short-term use; CBT-I for chronic insomnia.
When you prescribe a z-drug, do it short-term, counsel about complex behaviors and next-day impairment, and have a plan for what comes after.